Novo Nordisk's sales increased by 19% in Danish kroner and by 18% at constant exchange rates to USD 11.0 billion in the first three months of 2025

FDA accepts filing application for oral semaglutide 25 mg, which if approved, would be the first oral GLP-1 treatment for obesity

Novo Nordisk announces that CVS Caremark®, the country's largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies